...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: you won’t see anyone buying this

KK2 - What was the share count at the time of the spin out in 2013? Divide that number into the current share tally and multiply by 100. I was very generous in favour of management saying 300%.

tada

Share
New Message
Please login to post a reply